Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.

An initial relatively small eGFR decrease may be expected after empagliflozin initiation. Such small eGFR decrease was not associated with adverse cardiovascular outcomes with empagliflozin. In contrast, eGFR decrease was associated with poor cardiovascular outcomes with placebo.